FrancophonIA/ELRC3.0 huggingface dataset:
English: Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive chemotherapy.
Croatian: Primjena filgrastima samog ne znači da će se spriječiti pojava trombocitopenije i anemije, izazvana mijelosupresijskom kemoterapijom.
English: The assessment of undesirable effects is based on the following frequency data: Very common:
Croatian: Nuspojave su prema učestalosti razvrstane na sljedeći način: Vrlo česte:
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer Carton
Croatian: PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU Kutija
English: In clinical trials, the most frequent undesirable effects attributable to filgrastim at the recommended dose were mild or moderate musculoskeletal pain, occurring in 10 %, and severe musculoskeletal pain in 3 % of patients.
Croatian: U kliničkim su ispitivanjima najučestalije nuspojave, koje su se mogle pripisati filgrastimu primijenjenom u preporučenim dozama, bile blaga do umjerena bol u mišićno-koštanom sustavu koja se javila u 10 % bolesnika, i jaka bol u mišićno-koštanom sustavu, koja se javila u 3 % bolesnika.
English: Initial dose adjustment to alternate day dosing with 30 MIU (300 μg)/day by subcutaneous injection is recommended.
Croatian: Preporučuje se početno prilagođavanje doze na 30 MIU (300 μg) u supkutanoj injekciji svaki drugi dan.
English: If you are acting as a stem cell donor for another person, the usual dose is 1 million international units (MIU) per kilogram bodyweight each day.
Croatian: Ako ćete svoje matične stanice darovati drugoj osobi, uobičajena doza je 1 milijun internacionalnih jedinica [MIU] po kilogramu tjelesne težine na dan.
English: Biograstim is supplied in packs of 1, 5 or 10 pre-filled syringes or multipacks of 10 (2 packs of 5) pre-filled syringes.
Croatian: Biograstim je dostupan u pakiranju od 1, 5 ili 10 napunjenih štrcaljki ili u višestrukom pakiranju od 10 (2 pakiranja od 5) napunjenih štrcaljki.
English: Do not use this medicine after the expiry date which is stated on the outer carton and on the pre-filled syringe after EXP.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i napunjenoj štrcaljki iza oznaka "Rok valjanosti" ili "EXP".
English: 9/L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections 1.0 x 10 when other options to manage neutropenia are inappropriate.
Croatian: Biograstim je indiciran za liječenje perzistentne neutropenije (ABN 1,0 x 109/l ili manji) u bolesnika s uznapredovalom HIV-infekcijom, sa svrhom da se smanji rizik od bakterijskih infekcija, kada druge mogućnosti liječenja neutropenije nisu prikladne.
English: The safety and efficacy of filgrastim have not been assessed in normal donors < 16 years or > 60 years.
Croatian: Sigurnost i djelotvornost primjene filgrastima u zdravih davatelja mlađih od 16 godina i starijih od 60 godina nisu ispitane.
English: Complete blood cell counts with differential and platelet counts and an evaluation of bone marrow morphology and karyotype should be performed prior to treatment.
Croatian: Prije početka primjene lijeka treba napraviti kompletnu i diferencijalnu krvnu sliku, odrediti broj trombocita, evaluirati morfologiju koštane srži i obaviti kariotipizaciju.
English: Each mL of solution for injection or infusion contains 60 million international units [MIU] (600 microgram) of filgrastim.
Croatian: Jedan ml otopine za injekciju ili infuziju sadrži 60 milijuna internacionalnih jedinica [MIU] (600 mikrograma) filgrastima.
English: Current data indicate that immunological interactions between the allogeneic PBPC graft and the recipient may be associated with an increased risk of acute and chronic GvHD when compared with bone marrow transplantation.
Croatian: Postojeći podaci pokazuju da imunološke interakcije između presađenih alogenih progenitorskih stanica periferne krvi i primatelja mogu biti povezane s većim rizikom od akutne transplantacijske bolesti, nego pri presađivanju koštane srži.
English: Decreased glucose, elevated alkaline phosphatase, elevated LDH, hyperuricaemia
Croatian: Snižena glukoza, povišena alkalna fosfataza, povišena LDH, hiperuricemija
English: It is unknown whether filgrastim is excreted in human breast milk.
Croatian: Nije poznato izlučuje li se filgrastim u majčino mlijeko u ljudi.
English: Following termination of filgrastim therapy, circulating neutrophil counts decrease by 50 % within 1 to 2 days, and to normal levels within 1 to 7 days.
Croatian: Po okončanju primjene filgrastima broj neutrofila u perifernoj krvi obično se za 1 do 2 dana smanji za 50 %, a 1 do 7 dana nakon toga ponovno se normalizira.
English: Premature discontinuation of filgrastim therapy prior to the time of the expected neutrophil nadir is not recommended.
Croatian: Ne preporučuje se prerana obustava filgrastima, tj. obustava prije vremena očekivanog najmanjeg broja neutrofila.
English: Regular urinanalysis should be performed to monitor this event.
Croatian: Tu pojavu treba nadzirati redovitim pretragama urina.
English: Mobilisation of PBPC does not provide a direct clinical benefit to normal donors and should only be considered for the purposes of allogeneic stem cell transplantation.
Croatian: Zdravi davatelj nema izravne kliničke koristi od mobilizacije progenitorskih stanica periferne krvi te o tom postupku treba razmišljati samo u svrhu alogeničnog presađivanja matičnih stanica.
English: If required, Biograstim may be diluted in glucose 50 mg/mL (5 %) solution for infusion.
Croatian: Ukoliko je potrebno, Biograstim se može razrijediti s 5 %--tnom otopinom glukoze za infuziju (50 mg/ml).
English: Each pre-filled syringe contains 30 MIU (300 µg) of filgrastim in 0.5 mL solution for injection or infusion.
Croatian: Jedna napunjena štrcaljka sadrži 30 MIU (300 μg) filgrastima u 0,5 ml otopine za injekciju ili infuziju.
English: Rare pulmonary undesirable effects, in particular interstitial pneumonia, have been reported after G-CSF administration.
Croatian: Pri primjeni G-CSF-a prijavljene su rijetke plućne nuspojave, osobito intersticijska pneumonija.
English: The usual starting dose is 1 million international units (MIU) per kilogram of bodyweight each day.
Croatian: Uobičajena početna doza je 1 milijun internacionalnih jedinica [MIU] po kilogramu tjelesne težine na dan.
English: Cases of capillary leak syndrome have been reported in the postmarketing setting with G-CSF use.
Croatian: Slučajevi sindroma povećane propusnosti kapilara uz primjenu G-CSF-a prijavljeni su nakon stavljanja lijeka na tržište.
English: The recommended starting dose is 1.2 MIU (12 μg)/kg/day subcutaneously as a single dose or in divided doses.
Croatian: Preporučena početna doza je 1,2 MIU (12 μg)/kg/dan supkutano, u jednokratnoj ili u podijeljenim dozama.
English: Very common (may affect more than 1 in 10 people): - reduction in red blood cells, which can make the skin pale and cause weakness or breathlessness; - low blood levels of glucose; elevated levels of some blood enzymes; high blood levels of uric acid; - nosebleed.
Croatian: Vrlo često (mogu se javiti u više od 1 na 10 osoba): - smanjeni broj crvenih krvnih stanica, što uzrokuje bljedilo kože, slabost ili nedostatak zraka; - snižena razina glukoze u krvi; povišene razine nekih jetrenih enzima ili krvnih enzima; visoka razina mokraćne kiseline u krvi; - krvarenje iz nosa.
English: Special precautions in patients with HIV infection Blood cell counts
Croatian: Posebne mjere opreza u bolesnika s HIV-infekcijom
English: Musculoskeletal pain
Croatian: Bol u mišićno-skeletnom sustavu
English: How do I inject Biograstim myself?
Croatian: Kako samostalno primijeniti Biograstim?
English: - Dispose of the full puncture-proof container as instructed by your doctor, nurse or pharmacist.
Croatian: - Pun neprobojni spremnik zbrinite na način kako su Vam objasnili liječnik, medicinska sestra ili ljekarnik.
English: In cancer patients, the pharmacokinetic profile of Biograstim and the reference product was comparable after single and repeated subcutaneous administration.
Croatian: Farmakokinetički profili Biograstima i referentnog lijeka bili su u onkoloških bolesnika usporedivi i nakon jednokratne i nakon višekratnih doza.
English: Elevated alkaline phosphatase, elevated LDH
Croatian: Povišena alkalna fosfataza, povišeni LDH
English: Biograstim 48 MIU/0.8 mL: Each pre-filled syringe contains 48 million international units [MIU] (480 microgram) of filgrastim in 0.8 mL solution.
Croatian: Biograstim 48 MIU/0,8 ml otopina za injekciju ili infuziju: jedna napunjena štrcaljka sadrži 48 milijuna internacionalnih jedinica [MIU] (480 mikrograma) filgrastima u 0,8 ml otopine.
English: Remove the syringe from the injection site while keeping your finger on the plunger (see picture 7).
Croatian: Nakon injiciranja tekućine, izvadite iglu zadržavajući pritisak na klipu (vidjeti sliku 7).
English: In clinical studies, > 90 % of patients responded reached and can be maintained (ANC > 2.0 x 10 at these doses, achieving reversal of neutropenia in a median of 2 days.
Croatian: U kliničkim je ispitivanjima > 90 % ispitanika odgovorilo na te doze, a medijan vremena potrebnog za korekciju neutropenije iznosio je 2 dana.
English: Each pre-filled syringe contains 48 MIU (480 µg) of filgrastim in 0.8 mL solution for injection or infusion.
Croatian: Jedna napunjena štrcaljka sadrži 48 MIU (480 μg) filgrastima u 0,8 ml otopine za injekciju ili infuziju.
English: Filgrastim should be permanently discontinued in patients who experience a serious allergic reaction.
Croatian: Bolesnicima s ozbiljnom alergijskom reakcijom filgrastim treba trajno obustaviti.
English: Pull slightly on the plunger to check that a blood vessel has not been punctured.
Croatian: 3. Povucite lagano klip prema van, tako da provjerite da li ste možda pogodili krvnu žilu.
English: In view of limited safety and efficacy data in patients with secondary AML, filgrastim should be administered with caution.
Croatian: Budući da su podaci o sigurnosti primjene i djelotvornosti u bolesnika sa sekundarnom akutnim mijeloičnom leukemijom (AML) ograničeni, filgrastim tim bolesnicima treba davati oprezno.
English: In clinical studies, the only undesirable effects that were consistently considered to be related to filgrastim administration were musculoskeletal pain, predominantly mild to moderate bone pain and myalgia.
Croatian: Jedine nuspojave koja su se u kliničkim ispitivanjima dosljedno držale povezanima s primjenom filgrastima bile su bol u mišićno-koštanom sustavu, pretežno slaba do umjerena bol u kostima i mijalgija.
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Pre-filled syringe
Croatian: PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE Napunjena štrcaljka
English: Find a comfortable, well-lit place and put everything you need where you can reach them (the Biograstim pre-filled syringe and alcohol wipes).
Croatian: Pronađite udobno, dobro osvijetljeno mjesto i stavite sve što trebate tako da Vam je pri ruci
English: How to use Biograstim
Croatian: Kako primjenjivati Biograstim
English: The first dose of filgrastim should not be administered less than 24 hours following cytotoxic chemotherapy and within 24 hours of bone marrow infusion.
Croatian: Prvu dozu filgrastima treba dati najranije 24 sata nakon citotoksične kemoterapije i unutar 24 sata nakon infuzije koštane srži.
English: Filgrastim may be given as a daily subcutaneous injection or as a daily intravenous infusion diluted in glucose 50 mg/mL (5 %) solution for infusion given over 30 minutes (see section 6.6 for instructions on dilution).
Croatian: Filgrastim se može davati svakodnevno supkutanim injekcijama ili u intravenskoj infuziji tijekom 30 minuta, razrijeđen otopinom glukoze 50 mg/ml (5 %) za infuziju (za upute o razrjeđivanju vidjeti dio 6.6).
English: 1 pre-filled syringe containing 0.8 mL 5 pre-filled syringes containing 0.8 mL 5 pre-filled syringes with safety device containing 0.8 mL 10 pre-filled syringes containing 0.8 mL
Croatian: 1 napunjena štrcaljka koja sadrži 0,8 ml 5 napunjenih štrcaljki koje sadrže po 0,8 ml 5 napunjenih štrcaljki sa zaštitom za iglu koje sadrže po 0,8 ml 10 napunjenih štrcaljki koje sadrže po 0,8 ml
English: Very common (may affect more than 1 in 10 people): - rise in white blood cells; reduction in blood platelets, which increases risk of bleeding or bruising; - headache.
Croatian: Vrlo često (mogu se javiti u više od 1 na 10 osoba): - povećani broj bijelih krvnih stanica smanjeni broj trombocita u krvi, zbog čega se može povećati mogućnost pojave krvarenja ili modrica; - glavobolja.
English: Uncommon (may affect up to 1 in 100 people): - elevated levels of some liver enzymes; high blood levels of uric acid; - worsening of rheumatic conditions.
Croatian: Manje često (mogu se javiti do 1 na 100 osoba): - povišene razine nekih jetrenih enzima; visoka razina mokraćne kiseline u krvi; - pogoršanje reumatskih stanja.
English: For PBPC mobilisation in normal donors, filgrastim should be administered at 1.0 MIU (10 μg)/kg/day subcutaneously for 4 to 5 consecutive days.
Croatian: Za mobilizaciju progenitorskih stanica periferne krvi u zdravih davatelja filgrastim treba davati u dozi od 1,0 MIU (10 μg)/kg/dan supkutano tijekom 4-5 uzastopnih dana.
English: Special care should be taken in the diagnosis of severe chronic neutropenias to distinguish them from other haematopoietic disorders such as aplastic anaemia, myelodysplasia and myeloid leukaemia.
Croatian: Prijelaz u leukemiju ili mijelodisplastični sindrom Pri dijagnosticiranju teških kroničnih neutropenija nužan je poseban oprez, kako bi ih se razlikovalo od drugih hematopoetskih poremećaja, npr. aplastične anemije, mijelodisplazije i mijeloične leukemije.
English: Less frequent undesirable effects include urinary abnormalities predominantly mild or moderate dysuria.
Croatian: Među manje učestale nuspojave ubrajaju se mokraćni poremećaji, pretežno blaga do umjerena dizurija.
English: The recommended dose of filgrastim for PBPC mobilisation when used alone is 1.0 MIU (10 μg)/kg/day as a 24 hour subcutaneous continuous infusion or a single daily subcutaneous injection for 5 to 7 consecutive days.
Croatian: Kada se daje sam, preporučena doza filgrastima za mobilizaciju progenitorskih stanica periferne krvi je 1,0 MIU (10 μg)/kg/dan u kontinuiranoj supkutanoj infuziji tijekom 24 sata, ili u jednokratnoj supkutanoj injekciji jedanput na dan tijekom 5 do 7 uzastopnih dana.
English: Common but generally asymptomatic cases of splenomegaly and very rare cases of splenic rupture have been reported in healthy donors and patients following administration of G-CSFs (see section 4.4).
Croatian: U zdravih davatelja i u bolesnika prijavljivani su česti, općenito asimptomatski slučajevi splenomegalije, te vrlo rijetki slučajevi rupture slezene pri primjeni G-CSF-a (vidjeti dio 4.4).
English: In clinical as determined by the patient's ANC, to maintain the neutrophil count at > 2.0 x 10 studies, dosing with 30 MIU (300 μg)/day on 1 to 7 days per week was required to maintain the ANC
Croatian: U kliničkim je ispitivanjima za održavanje ukupnog broja neutrofila na vrijednostima > 2,0 x 109/l trebala doza od 30 MIU (300 μg)/dan tijekom 1 do 7 dana na tjedan, a medijan učestalosti doza iznosio je 3 dana na tjedan.
English: Your doctor will then test your blood to see how well your treatment is working and to find the dose that is best for you.
Croatian: Liječnik će potom odrediti da obavite krvne pretrage, da vidi kako lijek djeluje i da odredi koja je doza za Vas najbolja.
English: Your doctor will test your blood at regular intervals to see how well the treatment is working.
Croatian: Liječnik će odrediti da u pravilnim vremenskim razmacima obavljate krvne pretrage, da vidi kako lijek djeluje.
English: Your doctor will test your blood daily to see how well the treatment is working and to find the dose that is best for you.
Croatian: Liječnik će tražiti da svaki dan obavite krvne pretrage, da vidi kako lijek djeluje i da odredi koja je doza za Vas najbolja.
English: Transient increases with no clinical symptoms were observed in serum uric acid, lactic dehydrogenase and alkaline phosphatase.
Croatian: Bilo je prolaznog povišenja mokraćne kiseline u serumu, laktat dehidrogenaze i alkalne fosfataze, bez pojave kliničkih simptoma.
English: ≥ 1/100 to < 1/10
Croatian: ≥1/10 000 do <1/1 000,
English: Transient thrombocytopenia (platelets < 100 x 10 leukapheresis was observed in 35 % of subjects studied.
Croatian: Prolazna trombocitopenija (trombociti < 100 x 109/l) nakon primjene filgrastima i nakon leukafereze zabilježena je u 35 % ispitanika.
English: Do not attempt to self-administer without this training.
Croatian: Bez njihovih uputa nemojte pokušavati sami sebi davati injekcije.
English: Biograstim 30 MIU/0.5 mL solution for injection or infusion Biograstim 48 MIU/0.8 mL solution for injection or infusion
Croatian: Biograstim 30 MIU/0,5 ml otopina za injekciju ili infuziju Biograstim 48 MIU/0,8 ml otopina za injekciju ili infuziju filgrastim
English: Each pre-filled syringe contains 48 million international units [MIU] (480 microgram) of filgrastim in 0.8 mL (60 MIU/mL, 600 microgram/mL).
Croatian: Jedna napunjena štrcaljka sadrži 48 milijuna internacionalnih jedinica [MIU] (480 mikrograma) filgrastima u 0,8 ml otopine (60 MIU /ml, 600 mikrograma/ml).
English: 1 pre-filled syringe containing 0.5 mL 5 pre-filled syringes containing 0.5 mL 5 pre-filled syringes with safety device containing 0.5 mL 10 pre-filled syringes containing 0.5 mL
Croatian: 1 napunjena štrcaljka koja sadrži 0,5 ml 5 napunjenih štrcaljki koje sadrže po 0,5 ml 5 napunjenih štrcaljki sa zaštitom za iglu koje sadrže po 0,5 ml 10 napunjenih štrcaljki koje sadrže po 0,5 ml
English: The recommended starting dose is 0.5 MIU (5 μg)/kg/day subcutaneously as a single dose or in divided doses.
Croatian: Preporučena početna doza je 0,5 MIU (5 μg)/kg/dan supkutano, u jednokratnoj ili u podijeljenim dozama.
English: Discontinuation of filgrastim therapy usually results in a 50 % decrease in circulating neutrophils within 1 to 2 days, with a return to normal levels in 1 to 7 days.
Croatian: Pri prekidu primjene filgrastima broj neutrofila u perifernoj krvi obično se za 1 do 2 dana smanji za 50 %, a 1 do 7 dana nakon toga ponovno se normalizira.
English: Biograstim 30 MIU/0.5 mL: Each pre-filled syringe contains 30 million international units [MIU] (300 microgram) of filgrastim in 0.5 mL solution.
Croatian: Biograstim 30 MIU/0,5 ml otopina za injekciju ili infuziju: Jedna napunjena štrcaljka sadrži 30 milijuna internacionalnih jedinica [MIU] (300 mikrograma) filgrastima u 0,5 ml otopine.
English: Monitoring of bone density may be indicated in patients with underlying osteoporotic bone diseases who undergo continuous therapy with filgrastim for more than 6 months.
Croatian: U bolesnika s osteoporoznim bolestima kosti u podlozi, koji primaju filgrastim duže od 6 mjeseci, može biti indicirano praćenje gustoće kosti.
English: Patients who have undergone very extensive prior myelosuppressive therapy may not show sufficient mobilisation of PBPC to achieve the recommended minimum yield (2.0 x 10
Croatian: U bolesnika koji su prethodno primali ekstenzivnu mijelosupresijsku terapiju, mobilizacija progenitorskih stanica periferne krvi možda neće biti dovoljna da se dobije preporučeni minimalni broj stanica (2,0 x 106 CD34+ stanica/kg) ili da se u jednakom stupnju ubrza oporavak broja trombocita.
English: The effects of filgrastim on neutropenia due to bone marrow-infiltrating infection or malignancy have not been well established.
Croatian: Učinci filgrastima na neutropeniju prouzročenu infekcijom ili zloćudnom bolešću koja infiltrira koštanu srž nisu ispitani.
English: It is unknown whether filgrastim passes over to the breast milk.
Croatian: Nije poznato izlučuje li se filgrastim u majčino mlijeko.
English: Very common (may affect more than 1 in 10 people): - elevated levels of some liver or blood enzymes; high blood levels of uric acid; - feeling sick; vomiting; - chest pain.
Croatian: Vrlo često (mogu se javiti u više od 1 na 10 osoba): - povišene razine nekih jetrenih enzima ili krvnih enzima; visoka razina mokraćne kiseline u krvi; - mučnina; povraćanje; - bol u prsima.
English: Rheumatoid arthritis exacerbation
Croatian: Egzacerbacija reumatoidnog artritisa
English: Following established chemotherapy for solid tumours, lymphomas and lymphoid leukaemias, it is expected that the duration of treatment required to fulfil these criteria will be up to 14 days.
Croatian: Očekuje se da će primjena filgrastima nakon dokazano citotoksične kemoterapije za solidne tumore, limfome i limfocitne leukemije trajati do 14 dana.
English: It is quite normal to have a number of courses of Biograstim treatment.
Croatian: Uobičajeno je uzimati Biograstim u više navrata.
English: Once the neutrophil nadir has been passed the daily dose of filgrastim should be titrated against the neutrophil response as follows:
Croatian: Nakon što prođe najizraženije smanjenje broja neutrofila, dnevnu dozu filgrastima treba titrirati prema odgovoru neutrofila, prema niže navedenoj shemi.
English: In normal donors, pulmonary adverse events (haemoptysis, pulmonary haemorrhage, lung infiltration, dyspnoea and hypoxia) have been reported in postmarketing experience (see section 4.4).
Croatian: U normalnih davatelja, u postmarketinškom periodu zabilježene su plućne nuspojave (hemoptiza, plućna hemoragija, infiltracija pluća, dispneja i hipoksija) (vidjeti dio 4.4).
English: Undesirable effects related to filgrastim therapy in SCN patients have been reported and for some their frequencies tend to decrease with time.
Croatian: U bolesnika s teškom kroničnom neutropenijom prijavljivane su nuspojave povezane s primjenom filgrastima; učestalost nekih s vremenom se smanjivala.
English: The usual dose is 0.5 million international units (MIU) per kilogram of bodyweight each day.
Croatian: Uobičajena doza je 0,5 milijuna internacionalnih jedinica (engl. million international units, MIU) po kilogramu tjelesne težine svaki dan.
English: Clearance of filgrastim has been shown to follow first-order pharmacokinetics after both subcutaneous and intravenous administration.
Croatian: Pokazalo se da klirens filgrastima i nakon supkutane i nakon intravenske primjene slijedi obrazac farmakokinetičkih procesa prvog reda.
English: Each pre-filled syringe contains 30 million international units [MIU] (300 microgram) of filgrastim in 0.5 mL (60 MIU/mL, 600 microgram/mL).
Croatian: Jedna napunjena štrcaljka sadrži 30 milijuna internacionalnih jedinica [MIU] (300 mikrograma) filgrastima u 0,5 ml otopine (60 MIU /ml, 600 mikrograma/ml).
English: Your doctor will continue to test your blood regularly and will recommend the best dose for you.
Croatian: Liječnik će nastaviti pratiti Vašu krvnu sliku i odrediti koja je doza za Vas najbolja.
English: In patients with known bone marrow-infiltrating infections or malignancy, consider appropriate therapy for treatment of the underlying condition in addition to administration of filgrastim for treatment of neutropenia.
Croatian: U bolesnika s poznatom infiltracijom uzročnicima infekcije ili zloćudnom bolešću valja, povrh primjene filgrastima za ispravljanje leukopenije, razmotriti i primjenu prikladnog lijeka za liječenje stanja u podlozi.
English: Capillary leak syndrome*
Croatian: Sindrom povećane propusnosti kapilara*
English: For the mobilisation of PBPC in normal donors prior to allogeneic peripheral blood progenitor cell transplantation
Croatian: Za mobilizaciju progenitorskih stanica periferne krvi u zdravih davatelja prije presađivanja alogeničnih progenitorskih stanica periferne krvi
English: Filgrastim should be diluted in 20 mL of glucose 50 mg/mL (5 %) solution for infusion (see section 6.6 for instructions on dilution).
Croatian: Filgrastim treba razrijediti u 20 ml 50 mg/ml (5 %) otopine glukoze za infuziju (za upute o razrjeđivanju vidjeti dio 6.6).
English: Long-term treatment with Biograstim may be required to maintain a normal number of white cells in your blood.
Croatian: Možda će za održavanje normalnog broja bijelih stanica u krvi biti nužna dugotrajnija primjena lijeka Biograstim.